This is supported by the data demonstrating that breast cancer cells are unresponsive to PTH or PTHrP treatment, and by the fact that PTH and abaloparatide lack the PTHrP midregion, NLS, and C-terminus, which appear critically important for PTHrP to directly regulate breast tumor progression. This evidence concerns the gene PTH and breast neoplasm.